BARBARA ANN KARMANOS CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1995-01-01

Employees: 5K

Market Cap: -

Website: http://www.karmanos.org

Clinical Trials

Isoflavones and Radiation Therapy in Treating Patients With Localized Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2005-10-21

Last Posted Date: 2013-04-05

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 70

Registration Number: NCT00243048

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma

Phase 2

Completed

Conditions: Intraocular Melanoma
Melanoma (Skin)

First Posted Date: 2005-10-13

Last Posted Date: 2013-04-08

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 32

Registration Number: NCT00238329

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer

Phase 2

Completed

Conditions: Esophageal Cancer
Gastric Cancer

Interventions: Biological: Bevacizumab
Drug: Docetaxel
Drug: Oxaliplatin

First Posted Date: 2005-09-22

Last Posted Date: 2019-03-26

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 39

Registration Number: NCT00217581

Locations: 🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

and more 1 locations

Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma

Phase 2

Completed

Conditions: Melanoma (Skin)

First Posted Date: 2004-09-13

Last Posted Date: 2013-04-05

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Registration Number: NCT00004022

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Dolastatin 10 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Hormone Therapy

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2004-08-17

Last Posted Date: 2013-04-05

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Registration Number: NCT00003626

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
University of Colorado Cancer Center, Denver, Colorado, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Bryostatin 1 in Treating Patients With Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

First Posted Date: 2004-08-13

Last Posted Date: 2013-04-05

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Registration Number: NCT00003220

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Veterans Affairs Medical Center - Detroit, Detroit, Michigan, United States

Pyrazoloacridine in Treating Women With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2004-08-11

Last Posted Date: 2012-03-12

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 20

Registration Number: NCT00002585

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Bryostatin 1 in Treating Patients With Recurrent or Refractory Hodgkin's Disease

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2004-07-26

Last Posted Date: 2014-04-11

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Registration Number: NCT00003936

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Bryostatin 1 in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Leukemia
Lymphoma

First Posted Date: 2004-07-19

Last Posted Date: 2013-04-05

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Registration Number: NCT00002908

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Bryostatin 1 in Treating Patients With Myelodysplastic Syndrome

Phase 2

Completed

Conditions: Leukemia
Myelodysplastic Syndromes

First Posted Date: 2004-07-19

Last Posted Date: 2013-04-05

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Registration Number: NCT00003171

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy